The invention relates to compounds having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors. The compounds find use, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis ...
目前，在GLP-1药物的DS生产工段中，对企业产能制约最大的是纯化工段，这是GLP-1药物生产过程中共性且核心的产能提升瓶颈问题。诺和诺德和礼来都相继加速布局产能，2024年2月，诺和诺德宣布斥资165亿美元收购CDMO巨头Catalent以提高生产能力，2024年5月，礼来宣布其在印第安纳州黎巴嫩生产基地新投资额达53亿美元。即便如此...
2. https://eppro02.ativ.me/src/EventPilot/php/express/web/page.php?page=IntHtml&project=ADA23&id=789.3. Zhao J, et al.LBA 66Efficacy and safety of HRS9531, a novel dual GLP-1/GIP receptor agonist, in patients with type 2 diabetes mellitus (T2DM): a phase 2 trial. Presented ...
1. Sanyal AJ, Bedossa P, Fraessdorf M, et al. Glucagon and GLP-1 receptor dual agonist Survodutide improved liver histology in people with MASH and fibrosis: Results from a randomized, double-blind, placebo-control...
一夜之间,GLP-1领域炸开了锅。此前在Amylin(胰淀素)领域深耕的 诺和诺德 ,突然调转船头,选择license in了 礼来 一直在走的GLP-1/GIP/GCG三靶点激动剂路线,并且交易对方还是一家中国药企—— 联邦制药 。本次BD交易,单单一条管线,首付款就达到了2亿美元,后续的里程
药物靶点作用机制在研适应症药物最高研发状态(全球)药物类型在研机构GMA102/105(重组抗人GLP-1受体人源化单克隆抗体)GIP-1RGIP-1R激动剂2型糖尿病;肥胖;超重临床3期单克隆抗体鸿运…
3.Zhao J, et al.LBA 66Efficacy and safety of HRS9531, a novel dual GLP-1/GIP receptor agonist, in patients with type 2 diabetes mellitus (T2DM): a phase 2 trial. Presented at EASD annual meeting. 声明: 1. 本新闻旨在分享...
(生物谷Bioon.com) 参考文献 Eun Ran Kim et al. A GLP-1/GLP-2 receptor dual agonist to treat non-alcoholic steatohepatitis: targeting the gut-liver axis and microbiome. Hepatology. 2021 Nov 12. doi: 10.1002/hep.32235.
The invention relates to compounds having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors. The compounds find use, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis ...
多激动剂(poly-agonist)可同时模拟多种激素的作用。临床试验已表明,一些多激动剂在治疗肥胖和2型糖尿病方面具有极好的前景,并已进入2期和3期临床试验。今年,在美国,第一种用于治疗2型糖尿病的双激动剂(dual agonist)药物已被批准上市。这种双激动剂药物结合了GLP-1和GIP(glucose-dependent insulinotropic polypeptide...